ARGENX SE's ticker is ARGX and the CUSIP is 04016X101. A total of 323 filers reported holding ARGENX SE in Q1 2024. The put-call ratio across all filers is 0.99 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $2,031 | +3.0% | 4,721 | -5.7% | 0.04% | +2.6% |
Q1 2024 | $1,972 | +0.1% | 5,007 | -3.3% | 0.04% | -7.3% |
Q4 2023 | $1,970 | -26.2% | 5,179 | -3.0% | 0.04% | -32.8% |
Q3 2023 | $2,671 | -16.5% | 5,339 | -14.1% | 0.06% | -11.6% |
Q2 2023 | $3,200 | +43.0% | 6,213 | +3.5% | 0.07% | +30.2% |
Q1 2023 | $2,237 | +9.3% | 6,004 | +11.1% | 0.05% | +3.9% |
Q4 2022 | $2,046 | -99.9% | 5,403 | -2.6% | 0.05% | -5.6% |
Q3 2022 | $1,958,000 | -9.7% | 5,545 | -3.1% | 0.05% | -3.6% |
Q2 2022 | $2,168,000 | +22.6% | 5,722 | +2.1% | 0.06% | +43.6% |
Q1 2022 | $1,768,000 | -0.5% | 5,607 | +10.5% | 0.04% | 0.0% |
Q4 2021 | $1,777,000 | +3.9% | 5,074 | -10.4% | 0.04% | -2.5% |
Q3 2021 | $1,711,000 | +8.0% | 5,665 | +7.7% | 0.04% | +8.1% |
Q2 2021 | $1,584,000 | +5.7% | 5,260 | -3.3% | 0.04% | 0.0% |
Q1 2021 | $1,499,000 | -10.0% | 5,442 | -3.9% | 0.04% | -11.9% |
Q4 2020 | $1,665,000 | +15.7% | 5,662 | +3.3% | 0.04% | +5.0% |
Q3 2020 | $1,439,000 | +12.6% | 5,483 | -3.4% | 0.04% | +8.1% |
Q2 2020 | $1,278,000 | – | 5,675 | – | 0.04% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Darwin Global Management, Ltd. | 285,198 | $106,259,071 | 29.06% |
Avoro Capital Advisors LLC | 1,287,500 | $479,696,750 | 7.11% |
Paradigm Biocapital Advisors LP | 181,172 | $67,501,064 | 6.40% |
DCF Advisers, LLC | 25,700 | $9,575,310 | 5.86% |
Artia Global Partners LP | 36,404 | $13,563,402 | 5.01% |
Bellevue Group AG | 886,928 | $330,451,634 | 4.80% |
Fairmount Funds Management LLC | 73,526 | $27,394,317 | 4.71% |
Eagle Health Investments LP | 64,400 | $23,994,152 | 4.67% |
Decheng Capital Management III (Cayman), LLC | 27,429 | $10,219,497 | 4.12% |
RTW INVESTMENTS, LP | 482,195 | $179,656,213 | 3.74% |